S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant pleural mesothelioma
• * Unresectable disease
• Must have measurable or nonmeasurable disease by RECIST or modified RECIST criteria
• Must have received prior systemically administered\* platinum-based chemotherapy and meets the following criteria:
• * No more than 2 prior systemic therapeutic regimens allowed (including biologics, targeted, and immunotherapies)
• * At least 1 regimen must have been platinum-based
• * Neoadjuvant and/or adjuvant systemic therapy is not counted as a prior regimen, assuming ≥ 12 weeks have elapsed between the end of neoadjuvant/adjuvant therapy and development of progressive disease NOTE: \*Pleural space washing with cisplatin does not constitute systemic administration
• No known CNS metastases
• PATIENT CHARACTERISTICS:
• Zubrod performance status 0-1
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Serum bilirubin normal
• AST or ALT ≤ 1.5 times upper limit of normal (ULN)
• Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No evidence of bleeding diathesis or coagulopathy
• * Previous pulmonary embolism allowed provided the patient is on therapeutic low molecular weight heparin injections or warfarin AND no evidence of bleeding
• * Patients on therapeutic warfarin must have an INR of \< 5 within 28 days prior to registration
• No pathologic condition other than mesothelioma that carries a high risk of bleeding
• No known HIV positivity
• No gastrointestinal tract disease resulting in an inability to take oral or enteral medication via a feeding tube or a requirement for IV alimentation, or active peptic ulcer disease
• No other prior malignancy allowed except for any of the following:
• * Adequately treated basal cell or squamous cell skin cancer
• * In situ cervical cancer
• * Adequately treated stage I or II cancer from which the patient is currently in complete remission
• * Any other cancer from which patient has been disease-free for 5 years
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from all prior therapy
• At least 28 days since prior systemic therapy (42 days for nitrosoureas or mitomycin C)
• At least 28 days since prior thoracic or other major surgery (e.g., pleurectomy or pleurodesis) and no anticipated need for major surgical procedures during study
• At least 14 days since prior radiotherapy
• No prior surgical procedure affecting absorption
• No prior chronic, systemic corticosteroids or other immunosuppressive agent, except corticosteroids equivalent to prednisone ≤ 20 mg daily
• * Must have been on a stable dosage regimen for ≥ 4 weeks
• * Topical and inhaled corticosteroids allowed
• No prior mTOR inhibitor therapy (i.e., rapamycin, everolimus, or temsirolimus)
• No concurrent immunization with attenuated live vaccines
• No concurrent antiretroviral therapy for HIV-positive patients
• No other concurrent investigational therapy
• No other concurrent anticancer agents